Skip to main content
. 2016 May 3;6:25286. doi: 10.1038/srep25286

Figure 6. hENT1 is involved in FTD incorporation in tumor cells.

Figure 6

(A) Concentration-dependent FTD incorporation in human cancer cell lines and fibroblasts. HCT-116, RKO, A549, WI38, and BJ cells were cultured in the presence of FTD for 1 hour. Data from fluorescence imaging using anti-BrdU antibody (3D4) are shown. (B) Relative expression level of SLC29A1 and SLC29A2 mRNA. Expression level of each gene in HCT-116 cells was set as 1. (C) Abrogation of FTD incorporation by the human nucleoside transporter inhibitor dipyridamole in human cancer cell lines. Bars indicate the relative integrated intensity of Alexa 488 (FTD) in the nuclei of cells treated with 1 μM FTD (the integrated intensity of FTD-treated cells (1 μM) was set as 1) and error bars show the SD of four different areas. (D) Assessment of the expression level of SLC29A1and SLC29A2 genes by quantitative PCR in siRNA-treated HCT-116 cells. (E) Suppression of FTD incorporation by siRNA-mediated knockdown of the SLC29A1 gene in HCT-116 cells. Bars indicate the average relative integrated intensity of Alexa 488 (FTD) in the nuclei of cells treated with FTD (the integrated intensity at 1 μM FTD in siGL2-treated cells was set as 1) and error bars show the SD of three independent experiments. Statistical analysis was done by the unpaired t-test. *p < 0.05, **p < 0.01.